(1.30%) 5 130.00 points
(1.25%) 38 705 points
(2.03%) 16 162 points
(-0.87%) $78.26
(5.31%) $2.14
(0.03%) $2 310.30
(-0.44%) $26.71
(0.37%) $966.20
(-0.35%) $0.929
(-1.25%) $10.85
(-0.10%) $0.797
(0.38%) $91.47
4 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 10.48%
4.41% $ 1.775
@ $3.29
Wydano: 14 vas. 2024 @ 20:44
Zwrot: -46.05%
Poprzedni sygnał: vas. 14 - 16:31
Poprzedni sygnał:
Zwrot: 4.44 %
Live Chart Being Loaded With Signals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain...
Stats | |
---|---|
Dzisiejszy wolumen | 4.36M |
Średni wolumen | 4.57M |
Kapitalizacja rynkowa | 437.07M |
EPS | $0 ( 2024-05-02 ) |
Następna data zysków | ( $-0.200 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.22 |
ATR14 | $0.00700 (0.39%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-28 | Swain Judith L | Buy | 8 032 | Common Stock |
2024-04-28 | Swain Judith L | Sell | 8 032 | Restricted Stock Units |
2024-04-28 | Sobecki Christopher J | Buy | 8 032 | Common Stock |
2024-04-28 | Sobecki Christopher J | Sell | 8 032 | Restricted Stock Units |
2024-04-28 | Lefkowitz Robert J Md | Buy | 8 032 | Common Stock |
INSIDER POWER |
---|
77.53 |
Last 98 transactions |
Buy: 8 163 755 | Sell: 972 585 |
Wolumen Korelacja
Lexicon Pharmaceuticals Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
FAT | 0.892 |
MORF | 0.876 |
PCVX | 0.869 |
ADVM | 0.864 |
GANX | 0.864 |
MREO | 0.857 |
BNIXU | 0.851 |
BASE | 0.849 |
FCBP | 0.839 |
CSX | 0.835 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Lexicon Pharmaceuticals Korelacja - Waluta/Towar
Lexicon Pharmaceuticals Finanse
Annual | 2023 |
Przychody: | $1.20M |
Zysk brutto: | $565 000 (46.93 %) |
EPS: | $-0.800 |
FY | 2023 |
Przychody: | $1.20M |
Zysk brutto: | $565 000 (46.93 %) |
EPS: | $-0.800 |
FY | 2022 |
Przychody: | $139 000 |
Zysk brutto: | $-288 000 (-207.19 %) |
EPS: | $-0.620 |
FY | 2021 |
Przychody: | $298 000 |
Zysk brutto: | $298 000 (100.00 %) |
EPS: | $-0.602 |
Financial Reports:
No articles found.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej